Loading…
Reported covered position: Director, Government Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medication Therapy Management Benefits Act of 2011
Client: AMERICAN PHARMACISTS ASSOCIATION · Firm: AMERICAN PHARMACISTS ASSOCIATION
S. 274 Medication Therapy Management Empowerment Act of 2011. H.R. 891 Medication Therapy Management Benefits Act of 2011. Agency issues related to standardized medication action plans; accountable care organizations (ACOs); pharmacists' participation in CMS Innovation Center initiatives; coverage for outpatient drugs; transparency and reporting of physician investment interests (Sunshine Act); potential new paradigm for drugs; essential health benefits (EHB); and standardized pharmacy notice.
Medication Therapy Management Benefits Act of 2011
Client: AMERICAN PHARMACISTS ASSOCIATION · Firm: AMERICAN PHARMACISTS ASSOCIATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN PHARMACISTS ASSOCIATION via AMERICAN PHARMACISTS ASSOCIATION
2012 · second_quarter · Q2
HCR(PL 111-152/111-148) concerning Medicare PartD;MTM;DME;transitions of care;pharmacy reibursement; loan forgiveness;agency issues concerning risk evaluation mitigation strategies;PDUFA;prescription drug monitoring program,drug abuse,safe drug supply chain;standardized medication action plans;personalized medication lists;ACOs;pharmacists role in CMS Innovation Center initiatives;standardized pharmacy notice;immunization;HIT; medication disposal;biosmiliars;EHB
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE
Source: Senate LDA
S. 2.74 Medication Therapy Management Empowerment Act of 2011. H.R. 891 Medication Therapy management Benefits Act of 2011. Agency issues related to standardized medication action plans; accountable care organizations; pharmacists' participation in the CMS Innovation Center initiatives; personalized medication lists; essential health benefits; and standardized pharmacy notice.
Medication Therapy Management Benefits Act of 2011
Client: AMERICAN PHARMACISTS ASSOCIATION · Firm: AMERICAN PHARMACISTS ASSOCIATION
S.274 Medication Therapy Management Empowerment Act of 2011 H.R.891 Medication Therapy Management Benefits Act of 2011 Agency issues related to standardized medication action plans; accountable care organizations; pharmacists' participation in the CMS Innovation Center initiatives; personalized medication lists; standardized pharmacy notice. immunization; and health information technology. Communications with the Joint Select Committee on Deficit Reduction on preserving patient access to medication therapy management services in Medicare Part D, fair reimbursement in Medicare and Medicaid.
2012 · first_quarter · Q1
Legislative and agency issues regarding the Patient Protection and Affordable Care Act (P.L. 111-148) - Appropriations for the medication therapy management grant program.
S. 274 Medication Therapy Management Empowerment Act of 2011. H.R. 891 Medication Therapy Management Benefits Act of 2011. Agency issues related to standardized medication action plans; accountable care organizations (ACOs); pharmacists' participation in CMS Innovation Center initiatives; coverage for outpatient drugs; transparency and reporting of physician investment interests (Sunshine Act); potential new paradigm for drugs; essential health benefits (EHB); and standardized pharmacy notice.
Legislative and agency issues regarding drug shortages, the reauthorization of the Prescription Drug User Fee Act (PDUFA), drug counterfeiting, supply chain integrity, drug diversion and controlled substance monitoring. Also, the Health Care and Education Reconciliation Act of 2010 (P.L. 111-145) and the Patient Protection and Affordability Act (P.L. 111-148) including sections concerning Medicare Part D changes; medication therapy management (MTM); accountable care organizations (ACOs); durable medical equipment (DME); Center for Medicare and Medicaid Innovation within CMS; transitions of care; essential health benefits (EHB); and providing adequate pharmacy reimbursement (AMP).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN PHARMACISTS ASSOCIATION via AMERICAN PHARMACISTS ASSOCIATION
2011 · fourth_quarter · Q4
Legislative and agency issues regarding the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152) and the Patient Protection and Affordable Care Act (P.L. 111-148) including sections concerning Medicare Part D changes; medication therapy management (MTM); accountable care organizations (ACOs); durable medical equipment (DME); Center for Medicare and Medicaid Innovation within CMS; transitions of care; essential health benefits; and providing adequate pharmacy reimbursement (AMP).
S. 2.74 Medication Therapy Management Empowerment Act of 2011. H.R. 891 Medication Therapy management Benefits Act of 2011. Agency issues related to standardized medication action plans; accountable care organizations; pharmacists' participation in the CMS Innovation Center initiatives; personalized medication lists; essential health benefits; and standardized pharmacy notice.
Legislative and agency issues regarding the Patient Protection and Affordable Care Act (P.L. 111-148) - Appropriations for the medication therapy management grant program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN PHARMACISTS ASSOCIATION via AMERICAN PHARMACISTS ASSOCIATION
2011 · third_quarter · Q3
S.48 Pharmacist Loan Repayment Eligibility Act of 2011 Agency issues relating to risk evaluation and mitigation strategies (REMS); the Prescription Drug User Fee Act (PDUFA); prescription drug monitoring programs; prescription drug abuse; and safety of the drug supply chain.
Legislative and agency issues regarding the Patient Protection and Affordable Care Act (P.L. 111-148) - Appropriations for the medication therapy management grant program. Communications with the Joint Committee on Deficit Reduction on maintaining funding for Medicare Part D provisions such as medication therapy management programs and preserving patient access to pharmacist provided care services.
Legislative and agency issues regarding the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152) and the Patient Protection and Affordable Care Act (P.L. 111-148) including sections concerning Medicare Part D changes; medication therapy management (MTM); accountable care organizations (ACOs); durable medical equipment (DME); Center for Medicare and Medicaid Innovation within CMS; transitions of care; and providing adequate pharmacy reimbursement (AMP).
S.274 Medication Therapy Management Empowerment Act of 2011 H.R.891 Medication Therapy Management Benefits Act of 2011 Agency issues related to standardized medication action plans; accountable care organizations; pharmacists' participation in the CMS Innovation Center initiatives; personalized medication lists; standardized pharmacy notice. immunization; and health information technology. Communications with the Joint Select Committee on Deficit Reduction on preserving patient access to medication therapy management services in Medicare Part D, fair reimbursement in Medicare and Medicaid.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE